首页> 外文OA文献 >Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
【2h】

Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug

机译:肿瘤相关巨噬细胞充当纳米治疗性pt(IV)前药的缓释储库

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA-b-PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials.
机译:治疗性纳米粒子(TNP)旨在更安全有效地将药物递送给癌症,但由于对体内的了解有限,因此临床结果无法预测。在这里,我们使用肿瘤内TNP药代动力学和药效学的单细胞成像,以更好地理解其异质性行为。包含荧光铂(IV)前药和经过临床测试的聚合物平台(PLGA-b-PEG)的TNP模型可通过引导细胞向肿瘤相关的巨噬细胞(TAM)摄取来促进长时间的药物循环并改变蓄积。 TNP载体,其药物有效载荷和单细胞DNA损伤反应的同时成像显示,TAM充当了一个局部药物仓库,积累了重要的载体,破坏DNA的Pt有效载荷逐渐从该载体释放到邻近的肿瘤细胞中。相应地,TAM消耗减少了肿瘤内TNP的积累和功效。因此,纳米疗法选择TAM进行药物输送,这对TNP设计和选择患者进行试验具有重要意义。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号